Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 183

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 183
---
2024, respectively1,783 1,768 Additional paid-in capital2,820,404 2,764,880 Accumulated other comprehensive income939 2,020 Accumulated deficit(1,796,073)(1,538,984)Total stockholders' equity1,027,053 1,229,684 Total liabilities and stockholders’ equity$1,166,241 $1,374,180 

See accompanying notes to unaudited condensed consolidated financial statements.

3

Table of Contents

Denali Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Operating expenses:Research and development$102,696 $91,399 $218,923 $198,415 General and administrative32,267 25,194 61,620 50,430 Total operating expenses134,963 116,593 280,543 248,845 Gain from divestiture of small molecule programs— — — 14,537 Loss from operations(134,963)(116,593)(280,543)(234,308)Interest and other income, net10,844 17,567 23,454 33,480 Net loss$(124,119)$(99,026)$(257,089)$(200,828)Net loss per share, basic and diluted$(0.72)$(0.59)$(1.50)$(1.26)Weighted average number of shares outstanding, basic and diluted171,449,847168,831,329171,336,568159,117,759Comprehensive lossNet loss$(124,119)$(99,026)$(257,089)$(200,828)Other comprehensive loss:Net unrealized loss on marketable securities, net of tax(1,098)(1,363)(1,081)(3,302)Comprehensive loss$(125,217)$(100,389)$(258,170)$(204,130)

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

Denali Therapeutics Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)    

Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income